MedPath

Research for markers of bone quality

Completed
Conditions
Osteoporosis
10017322
Registration Number
NL-OMON31945
Lead Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
100
Inclusion Criteria

Postmenopausal women with a vertebral fracture and postmenopausal women without a vertebral fracture with high bone mineral density (T-score >-1 S.D.)

Exclusion Criteria

Medication influencing osteoclast function and formation (Bisphosphonates, Hormone Replacement Therapy, Strontium Ranelate, Teriparatide, Raloxifen)

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Osteoclast formation will be studied by staining them with a Tartrate Resistant<br /><br>Acid Phosphatase staining.<br /><br>Bone resorption will be studied using a pit-assay to determine the surface and<br /><br>the number of resorption pits.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>To study the expression of genetic markers of bone resorption and fractures,<br /><br>osteoclast will be seeded for RNA isolation. Furthermore, since osteoclast are<br /><br>derived from the hematopoietic line like lymfocytes, the PBMCs will be used to<br /><br>study the influence of lymfocytes and factors derived from lymfocytes on<br /><br>osteoclasts.<br /><br>Furhtermore blood will be collected as well to study biochemic and serum<br /><br>markers to be able to relate them to osteoporosis or other pathology.</p><br>
© Copyright 2025. All Rights Reserved by MedPath